- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10. | Why Did bioAffinity Technologies' Stock Slip In After-Hours Trading After A Big Day Of Gains? | 8 | Benzinga.com | ||
| 16.10. | bioAffinity stock soars after receiving patent allowance for AI lung cancer test | 1 | Investing.com | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 16.10. | Patent für KI-Lungenkrebstest beflügelt bioAffinity-Aktie | - | Investing.com Deutsch | ||
| 15.10. | bioAffinity Technologies, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 15.10. | Biotechnology company bioAffinity regains compliance with Nasdaq's continued listing rules | 4 | Seeking Alpha | ||
| 15.10. | bioAffinity Technologies erfüllt wieder Nasdaq-Anforderungen | 2 | Investing.com Deutsch | ||
| 09.10. | bioAffinity Technologies schließt registrierte Direktplatzierung über 1,8 Millionen US-Dollar ab | 1 | Investing.com Deutsch | ||
| 09.10. | bioAffinity Technologies closes $1.8 million registered direct offering | 1 | Investing.com | ||
| 08.10. | bioAffinity Technologies raises $1.8 million in registered direct offering | 1 | Investing.com | ||
| 08.10. | bioAffinity Technologies launches $1.8M direct financing | 1 | Seeking Alpha | ||
| 08.10. | bioAffinity Technologies nimmt 1,8 Millionen US-Dollar durch Direktangebot ein | 1 | Investing.com Deutsch | ||
| 08.10. | bioAffinity Technologies raises $1.8 million in direct offering | 2 | Investing.com | ||
| 08.10. | What's Driving bioAffinity Technologies' Big Pre-Market Surge? | 3 | Benzinga.com | ||
| 07.10. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.09. | bioAffinity Technologies closes $4.8 million public offering | 2 | Investing.com | ||
| 30.09. | bioAffinity Technologies schließt Kapitalerhöhung über 4,8 Mio. US-Dollar ab | 1 | Investing.com Deutsch | ||
| 29.09. | bioAffinity Technologies: Öffentliches Angebot soll 4,8 Millionen US-Dollar einbringen | 2 | Investing.com Deutsch | ||
| 29.09. | bioAffinity Technologies prices $4.8 million public offering; shares down over 30% | 3 | Seeking Alpha | ||
| 26.09. | Bioaffinity Technologies stock soars after lung cancer test aids early detection | 14 | Investing.com |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,546 | +5,00 % | Drei Säulen für starke Renditen: Warum Biotech-Zulieferer jetzt die wahren Gewinner an der Börse sind! | ||
| VIVORYON THERAPEUTICS | 1,614 | -2,06 % | Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,910 | +4,27 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities | ||
| ONCO-INNOVATIONS | 0,805 | -2,42 % | Onco-Innovations Limited: Onco-Innovations Announces Private Placement | Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / October 14, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H... ► Artikel lesen | |
| NEOVACS | 0,072 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 | The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| BIOLINERX | 2,905 | -1,19 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYBIN | 5,100 | -0,97 % | Cybin gibt Update zur Neuropsychiatrie-Plattform und bevorstehenden klinischen Meilensteinen | - Erfolgreich abgeschlossene Aufnahme von 36 Teilnehmern in die Phase-2-Studie zu CYB004, dem DMT-Programm (deuteriertes Dimethyltryptamin, "DMT") des Unternehmens zur
Behandlung der... ► Artikel lesen | |
| BIOARCTIC | 26,560 | 0,00 % | BioArctic stellt Nominierungsausschuss vor | ||
| NUCANA | 4,210 | 0,00 % | NuCana plc: NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 | NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death
Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738
BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| GENSIGHT BIOLOGICS | 0,113 | -5,38 % | GenSight Biologics Reports Cash Position as of September 30, 2025 | Cash position amounted to €0.6 million as of September 30, 2025
Successful closing of fundraising worth nearly EUR3.7 million on October 1, 2025
Cash position amounted to €3.6 million... ► Artikel lesen | |
| IMMUNOME | 16,000 | -0,37 % | Immunome: Neuer ADC-Wirkstoff zeigt Potenzial gegen Krebs-Resistenzen | ||
| PEPGEN | 4,620 | +2,67 % | PepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society | PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and... ► Artikel lesen | |
| ARCELLX | 84,07 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| NUVALENT | 90,89 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| QIAGEN | 42,375 | +0,25 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen |
BIOAFFINITY TECHNOLOGIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.